Real-life Security and Efficacy of DAA-based Therapy in HCV/HIV-Coinfected Patients
NCT02057003 · Status: UNKNOWN · Type: OBSERVATIONAL · Enrollment: 1000
Last updated 2016-10-17
Summary
The purpose of this study is to evaluate the efficacy and tolerability of DAA-based regimens in the clinical practice in HIV/HCV-coinfected patients.
Hypothesis: The efficacy and tolerability of DAA-based regimens in the clinical practice is different to what is observed in clinical trials in HIV/HCV-coinfected patients.
Conditions
- Hepatitis C, Chronic
- Human Immunodeficiency Virus
Interventions
- DRUG
-
DAA against HCV
Sponsors & Collaborators
-
Hospital Universitario Reina Sofia de Cordoba
collaborator OTHER_GOV -
Hospital Universitario Virgen de la Victoria
collaborator OTHER -
Fundación de Investigación Biomédica - Hospital Universitario de La Princesa
collaborator OTHER -
Hospital Regional de Malaga
collaborator OTHER -
Hospital Torrecárdenas
collaborator UNKNOWN -
Complejo Hospitalario Universitario de Huelva
collaborator OTHER -
Hospital Universitario Puerta del Mar
collaborator OTHER -
Hospital Universitario Virgen Macarena
collaborator OTHER -
Hospital La Línea
collaborator UNKNOWN -
Complejo Hospitalario de Jaén
collaborator UNKNOWN -
Hospital Universitario Puerto Real
collaborator OTHER -
Hospital Universitario de Canarias
collaborator OTHER -
Hospital Poniente
collaborator UNKNOWN -
Hospital Universitario Central de Asturias
collaborator OTHER -
Hospital Álvaro Cunqueiro
collaborator OTHER -
Hospital Universitario Virgen de la Arrixaca
collaborator OTHER -
Hospital Universitario de Gran Canaria
collaborator UNKNOWN -
Valme University Hospital
lead OTHER
Principal Investigators
-
Karin Neukam, PhD · Valme University Hospital
Eligibility
- Min Age
- 18 Years
- Sex
- ALL
- Healthy Volunteers
- No
Timeline & Regulatory
- Start
- 2012-01-31
- Primary Completion
- 2020-12-31
- Completion
- 2020-12-31
Countries
- Spain
Study Locations
More Related Trials
-
Benefit of DAA Therapy in HCV Monoinfected and HIV-HCV Coinfected Patients With Mixed Cryoglobulinemia
NCT03342261 ·Status: COMPLETED
-
Hepatic Safety of Currently Used Antiretroviral Regimens in Patients With Chronic Hepatitis Under Real Life Conditions
NCT01908660 ·Status: COMPLETED
-
Immune Monitoring of Hepatitis C Under DAA Therapy
NCT02904603 ·Status: UNKNOWN
-
Study of Hepatic Responses in Patients Receiving Direct-acting Anti-HCV Drugs
NCT02532907 ·Status: COMPLETED
-
Drug-Drug Intercations and Direct Acting Antiviral Agents Against HCV
NCT06928259 ·Status: RECRUITING
-
Pilot Study of Patients Chronic Hepatitis C in Co-infected HIV Patients Relapsers After Previous Therapies
NCT00530972 ·Status: COMPLETED ·Phase: PHASE4
-
An Observational Study on Long-Term Persistence of Resistant Mutations And Durability of Sustained Virological Response in Patients With Chronic Hepatitis C Treated With Direct Acting Antiviral (DAA)- Containing Regimens
NCT01168856 ·Status: TERMINATED
-
Pilot Study to Assess the Efficacy of and Tolerance to a QUadruple Therapy to Treat HIV-HCV Coinfected Patients Previously Null Responders
NCT01725542 ·Status: COMPLETED ·Phase: PHASE2
-
Analysis of the Impact of HCV Treatment by Last Generation Direct Antiviral Agents (DAA) on Antiviral Immunity and HIV DNA Reservoir in Coinfected HIV-HCV Patients
NCT03244371 ·Status: UNKNOWN ·Phase: NA
-
High Dose Versus Standard Dose of Ribavirin in Patients With Chronic Hepatitis C, Genotype 3
NCT00830609 ·Status: COMPLETED ·Phase: PHASE4
-
14 vs 24 Weeks HCV Treatment to Genotype 2/3 Patients With Rapid Virological Response
NCT00308048 ·Status: COMPLETED ·Phase: PHASE3
-
Efficacy of Pegylated Interferon Plus Ribavirin Plus Nitazoxanide in HCV Genotype 4 and HIV Coinfection
NCT01529073 ·Status: UNKNOWN ·Phase: PHASE2
-
Low Dose Peginterferon-α 2a for Chronic Hepatitis C, Genotypes 2 or 3, in HIV-coinfected Patients
NCT00553930 ·Status: COMPLETED ·Phase: PHASE4
-
The Safety and Efficacy of Daclatasvir and Asunaprevir With Chronic HCV Genotype 1b Infection and Chronic Renal Failure
NCT02580474 ·Status: COMPLETED ·Phase: PHASE4
-
HCV Reinfection in in HIV/HCV-coinfected Patients Achieving SVR by Antiviral Therapy
NCT04768517 ·Status: UNKNOWN
-
Very Rapid and Rapid Virological Response as Predictors of Response of HCV Tretment
NCT03480269 ·Status: UNKNOWN
-
Plasma Ribavirin Assay During Combination Therapy for Chronic Hepatitis C
NCT00209755 ·Status: TERMINATED ·Phase: NA
-
Direct-acting Antivirals and Hepatocellular Carcinoma Recurrence
NCT03197155 ·Status: COMPLETED
-
Thalidomide Plus Peginterferon and Ribavirin in Patients With Interferon Resistance
NCT00856804 ·Status: UNKNOWN ·Phase: PHASE2
-
Status of Chronic Liver Disease in Hepatitis C Virus (HCV) Patients Coinfected With Human Immunodeficiency Virus (HIV) in Andalusia
NCT02511496 ·Status: UNKNOWN
-
Safety, Tolerability, and Efficacy of Asunaprevir and Daclatasvir in Subjects Coinfected With HIV-HCV
NCT02124044 ·Status: COMPLETED ·Phase: PHASE2
-
Long Term Follow-up of Hepatitis C Cured Patients
NCT03246048 ·Status: COMPLETED
-
Evaluation of RIBAvirin Plasma COncentrations in Patients With Chronic Hepatitis C Infection Routinely Treated With Modern DAA Regimens
NCT02505243 ·Status: COMPLETED
-
A Study to Assess Resistance and Durability of Response to ABT-493 and/or ABT-530
NCT02441283 ·Status: COMPLETED ·Phase: PHASE2/PHASE3
-
Effectiveness, Safety and Clinical Outcomes of Paritaprevir/Ombitasvir/r+Dasabuvir 8 Weeks
NCT03122132 ·Status: COMPLETED